Group 1 - The core point of the article is that Jiangsu Hengrui Medicine Co., Ltd.'s subsidiary, Suzhou Hengrui Medicine Co., Ltd., has received approval from the National Medical Products Administration for the clinical trial of SHR-4298 injection, which is intended for the treatment of advanced solid tumors [1] - SHR-4298 injection is a self-developed Class 1 therapeutic biological product that has shown good anti-tumor activity in preclinical animal models [1] - The clinical trial application for SHR-4298 injection was accepted on July 8, 2025, and it meets the requirements for drug registration according to the relevant regulations [1] Group 2 - There are currently no similar drugs approved for marketing domestically or internationally [1] - The total research and development investment for the SHR-4298 injection project has reached approximately 28.79 million yuan [1]